6 Aptamers for Targeted Therapy
173
160. Kulkarni O, Pawar RD, Purschke W, Eulberg D, Selve N, Buchner K, Ninichuk V, Segerer
S, Vielhauer V, Klussmann S, Anders HJ (2007) Spiegelmer inhibition of CCL2/MCP-1
ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 18(8):2350–2358
161. Oberthur D, Achenbach J, Gabdulkhakov A, Buchner K, Maasch C, Falke S, Rehders
D, Klussmann S, Betzel C (2015) Crystal structure of a mirror-image L-RNA aptamer
(Spiegelmer) in complex with the natural L-protein target CCL2. Nat Commun 6:6923
162. Luster AD, Alon R, von Andrian UH (2005) Immune cell migration in inflammation: present
and future therapeutic targets. Nat Immunol 6(12):1182–1190
163. Sayyed SG, Hagele H, Kulkarni OP, Endlich K, Segerer S, Eulberg D, Klussmann S, Anders
HJ (2009) Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12,
which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of
type 2 diabetes. Diabetologia 52(11):2445–2454
164. Karin N, Razon H (2018) Chemokines beyond chemo-attraction: CXCL10 and its significant
role in cancer and autoimmunity. Cytokine 109 (1096–0023 Electronic):24–28
165. Ferrari SM, Ruffilli I, Colaci M, Antonelli A, Ferri C, Fallahi P (2015) CXCL10 in psoriasis.
Adv Med Sci 60(2):349–354
166. Schnabel CL, Babasyan S, Freer H, Wagner B (2019) CXCL10 production in equine
monocytes is stimulated by interferon-gamma. Vet Immunol Immunopathol 207:25–30
167. Marro ML, Daniels DA, McNamee A, Andrew DP, Chapman TD, Jiang MS, Wu Z, Smith
JL, Patel KK, Gearing KL (2005) Identification of potent and selective RNA antagonists of
the IFN-gamma-inducible CXCL10 chemokine. Biochemistry 44(23):8449–8460
168. Schwoebel F, van Eijk LT, Zboralski D, Sell S, Buchner K, Maasch C, Purschke WG,
Humphrey M, Zollner S, Eulberg D, Morich F, Pickkers P, Klussmann S (2013) The effects
of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus
monkeys. Blood 121(12):2311–2315
169. Testa U, Castelli G, Elvira P (2015) Experimental and investigational therapies for
chemotherapy-induced anemia. Expert Opin Investig Drugs 24(11):1433–1445
170. Vander Ark A, Cao J, Li X (2018) TGF-beta receptors: In and beyond TGF-beta signaling.
Cell Signal 52:112–120
171. Morikawa M, Derynck R, Miyazono K (2016) TGF-beta and the TGF-beta family: contextdependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol 8(5):a021873
172. Filippi CM, Juedes AE, Oldham JE, Ling E, Togher L, Peng Y, Flavell RA, von Herrath
MG (2008) Transforming growth factor-beta suppresses the activation of CD8+T-cells when
naive but promotes their survival and function once antigen experienced: a two-faced impact
on autoimmunity. Diabetes 57(10):2684–2692
173. Kang J, Lee MS, Copland JA 3rd, Luxon BA, Gorenstein DG (2008) Combinatorial selection
of a single stranded DNA thioaptamer targeting TGF-beta1 protein. Bioorg Med Chem Lett
18(6):1835–1839
174. Pastor F, Soldevilla MM, Villanueva H, Kolonias D, Inoges S, de Cerio AL, Kandzia R,
Klimyuk V, Gleba Y, Gilboa E, Bendandi M (2013) CD28 aptamers as powerful immune
response modulators. Mol Ther Nucleic Acids 2:e98
175. Soldevilla MM, Villanueva H, Bendandi M, Inoges S, Lopez-Diaz de Cerio A, Pastor F (2015)
2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and
bone-marrow aplasia. Biomaterials 67 (1878–5905 (Electronic):274–285
176. McNamara JO, Kolonias D, Pastor F, Mittler RS, Chen L, Giangrande PH, Sullenger B,
Gilboa E (2008) Multivalent 4-1BB binding aptamers costimulate CD8+T cells and inhibit
tumor growth in mice. J Clin Invest 118(1):376–386
177. Dollins CM, Nair S, Boczkowski D, Lee J, Layzer JM, Gilboa E, Sullenger BA (2008)
Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer.
Chem Biol 15(7):675–682
178. Ramaswamy V, Monsalve A, Sautina L, Segal MS, Dobson J, Allen JB (2015) DNA
aptamer assembly as a vascular endothelial growth factor receptor agonist. Nucleic Acid
Ther 25(5):227–234
173
160. Kulkarni O, Pawar RD, Purschke W, Eulberg D, Selve N, Buchner K, Ninichuk V, Segerer
S, Vielhauer V, Klussmann S, Anders HJ (2007) Spiegelmer inhibition of CCL2/MCP-1
ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 18(8):2350–2358
161. Oberthur D, Achenbach J, Gabdulkhakov A, Buchner K, Maasch C, Falke S, Rehders
D, Klussmann S, Betzel C (2015) Crystal structure of a mirror-image L-RNA aptamer
(Spiegelmer) in complex with the natural L-protein target CCL2. Nat Commun 6:6923
162. Luster AD, Alon R, von Andrian UH (2005) Immune cell migration in inflammation: present
and future therapeutic targets. Nat Immunol 6(12):1182–1190
163. Sayyed SG, Hagele H, Kulkarni OP, Endlich K, Segerer S, Eulberg D, Klussmann S, Anders
HJ (2009) Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12,
which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of
type 2 diabetes. Diabetologia 52(11):2445–2454
164. Karin N, Razon H (2018) Chemokines beyond chemo-attraction: CXCL10 and its significant
role in cancer and autoimmunity. Cytokine 109 (1096–0023 Electronic):24–28
165. Ferrari SM, Ruffilli I, Colaci M, Antonelli A, Ferri C, Fallahi P (2015) CXCL10 in psoriasis.
Adv Med Sci 60(2):349–354
166. Schnabel CL, Babasyan S, Freer H, Wagner B (2019) CXCL10 production in equine
monocytes is stimulated by interferon-gamma. Vet Immunol Immunopathol 207:25–30
167. Marro ML, Daniels DA, McNamee A, Andrew DP, Chapman TD, Jiang MS, Wu Z, Smith
JL, Patel KK, Gearing KL (2005) Identification of potent and selective RNA antagonists of
the IFN-gamma-inducible CXCL10 chemokine. Biochemistry 44(23):8449–8460
168. Schwoebel F, van Eijk LT, Zboralski D, Sell S, Buchner K, Maasch C, Purschke WG,
Humphrey M, Zollner S, Eulberg D, Morich F, Pickkers P, Klussmann S (2013) The effects
of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus
monkeys. Blood 121(12):2311–2315
169. Testa U, Castelli G, Elvira P (2015) Experimental and investigational therapies for
chemotherapy-induced anemia. Expert Opin Investig Drugs 24(11):1433–1445
170. Vander Ark A, Cao J, Li X (2018) TGF-beta receptors: In and beyond TGF-beta signaling.
Cell Signal 52:112–120
171. Morikawa M, Derynck R, Miyazono K (2016) TGF-beta and the TGF-beta family: contextdependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol 8(5):a021873
172. Filippi CM, Juedes AE, Oldham JE, Ling E, Togher L, Peng Y, Flavell RA, von Herrath
MG (2008) Transforming growth factor-beta suppresses the activation of CD8+T-cells when
naive but promotes their survival and function once antigen experienced: a two-faced impact
on autoimmunity. Diabetes 57(10):2684–2692
173. Kang J, Lee MS, Copland JA 3rd, Luxon BA, Gorenstein DG (2008) Combinatorial selection
of a single stranded DNA thioaptamer targeting TGF-beta1 protein. Bioorg Med Chem Lett
18(6):1835–1839
174. Pastor F, Soldevilla MM, Villanueva H, Kolonias D, Inoges S, de Cerio AL, Kandzia R,
Klimyuk V, Gleba Y, Gilboa E, Bendandi M (2013) CD28 aptamers as powerful immune
response modulators. Mol Ther Nucleic Acids 2:e98
175. Soldevilla MM, Villanueva H, Bendandi M, Inoges S, Lopez-Diaz de Cerio A, Pastor F (2015)
2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and
bone-marrow aplasia. Biomaterials 67 (1878–5905 (Electronic):274–285
176. McNamara JO, Kolonias D, Pastor F, Mittler RS, Chen L, Giangrande PH, Sullenger B,
Gilboa E (2008) Multivalent 4-1BB binding aptamers costimulate CD8+T cells and inhibit
tumor growth in mice. J Clin Invest 118(1):376–386
177. Dollins CM, Nair S, Boczkowski D, Lee J, Layzer JM, Gilboa E, Sullenger BA (2008)
Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer.
Chem Biol 15(7):675–682
178. Ramaswamy V, Monsalve A, Sautina L, Segal MS, Dobson J, Allen JB (2015) DNA
aptamer assembly as a vascular endothelial growth factor receptor agonist. Nucleic Acid
Ther 25(5):227–234